Oral Quercetin in Adult Patients as a Potential Nutraceutical against Coronavirus Disease 2019 (COVID-19)

Main Article Content

Juan Fernando Ibarra Aguilar
Gabriela Ariane Sanabria Báez
Fernando Galeano

Abstract

Aim: To establishing the use of oral Quercetin as a potential nutraceutical against Coronavirus Disease 2019.

Methods: A descriptive, prospective longitudinal study was carried out on 52 patients treated at the ECOMED-LAMB Clinic, in the period from the onset of Covid-19 in our country, March 3, 2020 to January 2021.

Results: Were studied 52 patients COVID-19 positive, 20 (38.4%) were in preventive treatment and 32 patients (61.5%) was administered biological therapy once the diagnosis, no difference was found between female or male sex and the predominant age was those over 60 years. Twenty-four patients (70.6%) have presented at least one comorbidity.

The association of hospitalization with preventive treatment was not significant (p=0.166), we observed difference in the evolution of the patients (p= 0.084).

Conclusions: Quercetin could prevent and decrease the duration of SARSCoV-2 infections, it is plausible to propose the prophylactic use of this flavonoid in order to achieve clinical benefits.

Keywords:
Clinical benefits, flavonoid, biological therapy, quercetin

Article Details

How to Cite
Aguilar, J. F. I., Báez, G. A. S., & Galeano, F. (2021). Oral Quercetin in Adult Patients as a Potential Nutraceutical against Coronavirus Disease 2019 (COVID-19). Journal of Advances in Medical and Pharmaceutical Sciences, 23(3), 1-7. https://doi.org/10.9734/jamps/2021/v23i330222
Section
Original Research Article

References

Mrityunjaya M, Pavithra V, Neelam R, Janhavi P, Halami PM, Ravindra PV. Immune-boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19. Front. Immunology. 2020;11:570122. DOI: 10.3389/fimmu.2020.570122

World Health Organization. Vigilancia mundial de la COVID-19 causada por la infección humana por el virus de la COVID-19. Available:https://apps.who.int/iris/handle/10665/331740

Gupta Dhyuti, SahooAjaya Kumar, Singh Alok. Ivermectin: Potential candidate for the treatment of COVID-19. Braz J Infect Dis [Internet]. 2020;24(4):369-371. [Cited 2021 Jan 15] Available:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702020000400369&lng=en Available:https://doi.org/10.1016/ j.bjid.2020.06.002

Moreira JC, Lima WG, da Cruz WS. Quercetin as a potential nutraceutic against coronavirus disease 2019 (COVID-19). Ars Pharmaceutica. 2021;62(1):85-89. DOI: 10.30827/ars.v62i1.15684

Palamar B, Gruzeva T. The estimation of economic effectiveness of preventive measures of non-in¬fectious diseases. Wiadomosci Lekarskie. 2019:31;72(8): 1532-1541.

Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 [in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49:215–219. DOI:10.3785/j.issn.1008-9292.2020.03.03

Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, et al. Quercetin, inflammation and immunity. Nutrients. 2016;8:167. DOI: 10.3390/nu8030167

Wu W, Li R, Li X, He J, Jiang S, Liu S, et al. Quercetin as an antiviral agent inhibits Influenza A Virus (IAV) entry. Viruses. 2015;8:6. DOI: 10.3390/v8010006

Ganesan S, Faris AN, Comstock AT, Wang Q, Nanua S, Hershenson MB, et al. Quercetin inhibits rhinovirus replication in vitro and in-vivo. Antiviral Research. 2012;94:258–71. DOI: 10.1016/j.antiviral.2012.03.005

Smith M, Smith JC. Repurposing therapeutics for COVID-19: Supercomputer-based docking to the SARSCoV-2 viral spike protein and viral spike protein-human ACE2 interface. Chem Rxiv [Preprint]; 2020. DOI: 10.26434/chemrxiv.11871402.v2

Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G, et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. Journal of Virology. 2004;78:11334–9. DOI: 10.1128/JVI.78.20.11334-11339.2004

Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARSCoV-2 related disease (COVID-19). Frontiers in Immunology. 2020;11:1451. DOI: 10.3389/fimmu.2020.01451

Carr AC, Maggini S. Vitamin C. Immune Function. Nutrients. 2017;9:1211. DOI: 10.3390/nu9111211

Furuya A, Uozaki M, Yamasaki H, Arakawa T, AritaKoyama MAH. Antiviral effects of ascorbic and dehydroascorbic acids in-vitro. International Journal of Molecular Medicine. 2008;22:541–5. DOI: 10.3892/ijmm_00000053

Olthof MR, Hollman PC, Vree TB, Katan MB. Bioavalabilities of quercetin-3- glucoside anda querce¬tin-4’-glucoside do not differ in humans. The Journal of Nutrition. 2000;130(5):1200-03.

Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical re¬view of the data related to the safety of quercetin and lack of evidence in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food and Chemical Toxicology. 2007;45(11): 2179-205.

Keller RH. Inventor; Phoenix Biosciences, Inc., assignee. Treatments for viral infections. United States Patent US. 2009; 7:479-498.

Andersen DO, Weber ND, Wood SG, Hughes BG, Murray BK, North JA. In-vitro virucidal activity of selected anthraquinones and anthraquinone derivatives. Antiviral Research. 1991;16(2): 185-96.

Semple SJ, Pyke SM, Reynolds GD, Flower RL. In-vitro antiviral activity of the anthraquinone chrys¬ophanic acid against poliovirus. Antiviral Res. 2001;49(3):169-78.

Kim HK, Jeon WK, Ko BS. Flavanone glycosides from Citrus junos and their anti-influenza virus ac¬tivity. Planta Medica. 2001;67(6):548-9.

Gonzalez O, Fontanes V, Raychaudhuri S, Loo R, Loo J, Arumugaswami V, et al. The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology. 2009;50(6):1756-64.

Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G, et al. Small molecules block ingtheentry of severe acute respiratory syndrome coronavirus into host cells. Journal of Virology. 2004;78(20):11334-9.

Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. Journal of the American Medical Association. 2003;289:2801–2809. DOI: 10.1001/jama.289.21.JOC30885

Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infection Disease. 2016;49:129–133. DOI: 10.1016/j.ijid.2016.06.015

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet. 2020;395:1054–1062. DOI: 10.1016/S0140-6736(20)30566-3

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Journal of the American Medical Association. 2020;323:1061–1069. DOI: 10.1001/jama.2020.1585